STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...
Healio

VIDEO: EVO ICL a ‘game-changing’ technology to treat myopia

Please provide your email address to receive an email when new articles are posted on . According to Dhaliwal, the EVO ICL has five openings that allow the aqueous to flow through the ICL and “bathe ...
Healio

VIDEO: EVO ICL more ‘forgiving’ than previous versions

Please provide your email address to receive an email when new articles are posted on . WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Audrey R. Talley Rostov, MD, shares ...
Yahoo Finance

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

New FDA expansion of U.S. age indication extends EVO ICL use for patients 21 to 60 years old – making EVO ICL available to nearly 8 million additional refractive patients Lens-based vision correction ...
Business Wire

STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision

Agreement is Largest Commitment to EVO ICL™ in the U.S. LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of ...
Business Wire

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

In parallel with these market trends, long-term clinical evidence for EVO ICL continues to strengthen. In the FDA clinical trial, 629 eyes were followed for three years, demonstrating a strong safety ...